These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28245774)

  • 1. Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.
    Duconge J; Hernandez-Suarez DF
    Curr Clin Pharmacol; 2017; 12(1):11-17. PubMed ID: 28245774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
    González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
    Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology.
    Li P; Cao M; Liu L; Chen L; Liang S; Wang Y
    BMC Pharmacol Toxicol; 2024 Jun; 25(1):34. PubMed ID: 38845014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of aspirin and clopidogrel resistance in peripheral arterial disease.
    Guirgis M; Thompson P; Jansen S
    J Vasc Surg; 2017 Nov; 66(5):1576-1586. PubMed ID: 28893489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
    Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Carotid Stent Thrombosis in an Ultrarapid Clopidogrel Metabolizer: Case Report and Literature Review.
    Toljan K; Jovanović I; Starčević K; Ljevak J; Blažević N; Radoš M; Poljaković Z
    Vasc Endovascular Surg; 2019 Oct; 53(7):602-605. PubMed ID: 31272299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
    Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
    Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
    Rosafio F; Lelli N; Mimmi S; Vandelli L; Bigliardi G; Dell'Acqua ML; Picchetto L; Pentore R; Ferraro D; Trenti T; Nichelli P; Zini A
    J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):1864-1873. PubMed ID: 28576652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study.
    Backovic D; Ignjatovic S; Rakicevic L; Novkovic M; Kusic-Tisma J; Radojkovic D; Strugarevic E; Calija B; Radak D; Kovac M
    Curr Vasc Pharmacol; 2016; 14(6):563-569. PubMed ID: 27411384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
    Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
    Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures.
    Nakagawa I; Park HS; Yokoyama S; Wada T; Hironaka Y; Motoyama Y; Takayama K; Kichikawa K; Nakase H
    J Stroke Cerebrovasc Dis; 2016 Jan; 25(1):163-71. PubMed ID: 26493334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of clopidogrel.
    O'Connor SA; Hulot JS; Silvain J; Cayla G; Montalescot G; Collet JP
    Curr Pharm Des; 2012; 18(33):5309-27. PubMed ID: 22724417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.